December 2009 breasts onkologian journal published a study to determine whether the attempted to improve the conservation status of the patient with metastatic lung cancer has improved over the last two decades in controlled clinical trials.Researchers in more than 100 000 patients in the phase IV-small cell lung cancer (NSCLC) identifies a SEER database using survival in 2005 and to assess the true advances in recent medical healthcare trends. Daniel Morgensztern, MD, Washington University School of Medicine and his team evaluation of more than 16 years of records in an unselected population representative patients and found a modest but statistically significant improvement in overall survival rates.Overall survival in the latter half of the year rose by 13.2% 19.4%, in addition to the two-year General. survival increased by 4.5% to 7.8%.
Researchers noted the conservation status of the earnings to be taken into account for the treatment of advanced NSCLC changes over the last two decades, including a new chemotherapy agents and the residual value of the use of chemotherapy altistusohjelmien, and molecularly targeted therapies for deployment.
Dr. Morgensztern "Sinkkulohkaisu several new elements development led to statistically significant improvement in survival between 1990 and 2005, is the year and the survival of the irtiotto has improved in only 6% during this period," says. "Only real progress can be achieved by a better understanding of tumor biology and the development of new therapies. "
Author: Justin234 Source
No comments:
Post a Comment